

Special Issue

Mesothelioma Epidemiology, Pathogenesis, Emerging Treatments and Pre-Clinical Models

Message from the Guest Editor

We are pleased to invite you to contribute to a Special Issue on 'Epidemiology, Pathogenesis, Emerging Treatments and Pre-clinical Models of Mesothelioma.' Mesothelioma is a rare and aggressive disease caused mainly due to exposure to asbestos or other toxic fibres. Unfortunately, there is no current curative modality effective against this cancer, and therefore, the prognosis remains dismal. Despite advancements in understanding the molecular mechanisms underlying this disease, there is still an urgent need for further research to facilitate early diagnosis and to identify new treatments (or rationale drug combinations) which could significantly improve patient outcomes. This Special Issue aims to publish cutting-edge research and advancements in the field of mesothelioma to address these aforementioned challenges. We welcome submissions of both original research articles and reviews.

Guest Editor

Dr. Francesca Pentimalli
Department of Medicine and Surgery, LUM University "Giuseppe DeGennaro", 70010 Casamassima, Italy

Deadline for manuscript submissions

30 April 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/182694

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)